Investigation about the diabetes treatment satisfaction and the usability of insulin injector by the change to insulin glargine U-300 in type 1 and type2 diabetes patients under treatment with sustained-release dissolution insulin

Investigation about the diabetes treatment satisfaction and the usability of insulin injector by the change to insulin glargine U-300 in type 1 and type2 diabetes patients under treatment with sustained-release dissolution insulin - Investigation about the diabetes treatment satisfaction and the usability of insulin injector by the change to insulin glargine U-300.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024122

Enrollment

Registered

2016-10-01

Start date

2016-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 diabetes mellitus and type 2 diabetes mellitus

Interventions

Patients who use sustained release dissolution insulin will be switched to Insulin glargine U300 at same dosage,except for in case there is necessity to change insulin dosage for clinical reason such

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patient who had a diagnosis of type 1 and 2 diabetes. 2) The patient who is more than HbA1C 7 % and receiving treatment with sustained-release dissolution insulin by once a day more than three months. 3) Male and Female,the age 20 years old or older.

Exclusion criteria

Exclusion criteria: 1) The patients are pregnant or have possibility of pregnancy. 2) The patients with hypersensitivity for Insulin Glargin U-300. 3) The patients with serious complications and considered inappropriate to participate in this study by the doctor in charge. 4) The patients whose HbA1c fluctuated more than 1.0% within the past three months.

Design outcomes

Primary

Measure	Time frame
usability and satisfaction of the change to insulin glargine U-300 by using Questionnaire	—

Secondary

Measure	Time frame
Change in bodyweight,insulin dose,glucose (fasting),HbA1c,GA,CPR,TG,TC,LDL-C,HDL-C,ALT(GPT),AST(GOT),GTP,Uric acid,Creatinine,Urine microalbumin,blood pressure,adverse events	—

Countries

Japan

Contacts

Public ContactTakujiro Iuchi

Saitama Medical University Hospital Department Endocrinology and Diabetes

takucchi@saitama-med.ac.jp049-276-1280

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026